CytoMed Therapeutics
GDTC
6 hedge funds and large institutions have $116K invested in CytoMed Therapeutics in 2026 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
1,561% more capital inflows, than outflows
Capital inflows: $120K | Capital outflows: $7.24K
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
100% more funds holding
Funds holding: 3 → 6 (+3)
1.05% more ownership
Funds ownership: 0.1% → 1.15% (+1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$31.3K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$28.8K |
| 3 |
StoneX Group
New York
|
+$24.7K |
| 4 |
HRT Financial
New York
|
+$23.5K |
| 5 |
Two Sigma Securities
New York
|
+$11.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
Axiom Investment Management
New York
|
-$7.24K |
GDTC Hedge Fund Activity: Q3 2026 in Review
6 of the 8,226 institutional investors tracked by Wall St. Rank reported a position in CytoMed Therapeutics (GDTC) for Q3 2026, worth a combined $116K — up 845% from $12.2K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new GDTC positions and 1 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $31.3K. The largest seller was Axiom Investment Management, exiting entirely with an estimated $7.24K sold.
- 6 institutional investors held CytoMed Therapeutics (GDTC) as of Q3 2026, up from 3 in Q2 2026.
- Funds reported $116K of CytoMed Therapeutics stock for Q3 2026, up 845% quarter-over-quarter.
- 4 funds opened new CytoMed Therapeutics positions in Q3 2026 and 1 closed out, a net change of +3 holders.
- The largest CytoMed Therapeutics buyer in Q3 2026 was UBS Group, an estimated $31.3K added.
- The largest CytoMed Therapeutics seller in Q3 2026 was Axiom Investment Management, an estimated $7.24K sold.
Based on aggregated 13F filings for Q3 2026.